+1 Recommend
    • Review: found
    Is Open Access

    Review of 'Diagnostics for Repurposed Drugs'

    Diagnostics for Repurposed DrugsCrossref
    Comprehensive and short overview on diagnostic requirements to support drug repurposing
    Average rating:
        Rated 4.5 of 5.
    Level of importance:
        Rated 4 of 5.
    Level of validity:
        Rated 4 of 5.
    Level of completeness:
        Rated 4 of 5.
    Level of comprehensibility:
        Rated 5 of 5.
    Competing interests:

    Reviewed article

    • Record: found
    • Abstract: found
    • Article: found
    Is Open Access

    Diagnostics for Repurposed Drugs

    Precision Diagnostics is a prerequisite for Precision Medicine by enabling a characterization of diseases on a molecular level leading to mechanism-based treatment. Giving the right drug to the right patient at the right dose and at the right time requires novel biomarker signatures to stratify patients accordingly. Diagnostics play an essential role in the context of drug repurposing, where existing drugs are investigated and repurposed for a new therapeutic use. They are important to identify the eligible patient population for a repurposed drug. Diagnostics are extremely valuable in determining which patients are most likely to benefit from a specific treatment. This way the effectiveness of a drug or combination of drugs is significantly increased and the chance of potential adverse effects is reduced. In addition to precise diagnostics in the wet-lab, both the patient recruitment and avoidance of adverse events can currently be supported by artificial intelligence (AI) based on empirical data sets (Cai, T. et al., 2021, Syrowatka, A. et al., 2022).

      Review information

      This work has been published open access under Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.

      Molecular medicine,Molecular biology,Bioinformatics & Computational biology,Pharmacology & Pharmaceutical medicine
      artificial intelligence,biomarker,multi-omics,diagnostics,repurposed drugs,mechanism-based

      Review text

      A short and well balanced account of the opportunitites and potential issues in supporting repurposing of approved drugs by state-of-the-art diagnostic approaches, including the use of multiomics and AI-based data interpretation. I miss a statement or small paragraph about the need for assay validation, batch-to-batch control, analyte stability, particularly when different patient populations are compared (issues with assay parallelity) in the endeavor to rationalize drug re-purposing. In addition, commenting on the validation of AI algorithms when clincal decisions are being taken and patient selection is being supported would ass value to the paper.


      Comment on this review